Pulse Biosciences (PLSE) 10-Q 3 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 29, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	Pulse Biosciences, Inc.
Entity Filer Category	Accelerated Filer
Entity Central Index Key	0001625101
Trading Symbol	plse
Amendment Flag	false
Document Type	10-Q
Document Fiscal Period Focus	Q1
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Current Fiscal Year End Date	--12-31
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Common Stock, Shares Outstanding		20,710,406

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 8,536	$ 51,103
Investments	44,265	8,480
Prepaid expenses and other current assets	550	779
Total current assets	53,351	60,362
Property and equipment, net	2,056	2,173
Intangible assets, net	5,046	5,213
Goodwill	2,791	2,791
Other asset	208	101
Total assets	63,452	70,640
Current liabilities:
Accounts payable	1,200	1,272
Accrued expenses	1,519	1,421
Deferred rent, current		415
Lease liability, current	396
Total current liabilities	3,115	3,108
Deferred rent, less current		1,198
Lease liability, less current	1,223
Total liabilities	4,338	4,306
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding
Common stock, $0.001 par value: authorized – 500,000 shares; issued and outstanding – 20,710 shares and 20,593 shares at March 31, 2019 and December 31, 2018, respectively	21	21
Additional paid-in-capital	144,887	142,032
Accumulated other comprehensive income (loss)	2	(1)
Accumulated deficit	(85,796)	(75,718)
Total stockholders' equity	59,114	66,334
Total liabilities and stockholders' equity	$ 63,452	$ 70,640

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Condensed Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,710,000	20,593,000
Common stock, shares outstanding	20,710,000	20,593,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations And Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Condensed Consolidated Statements Of Operations And Comprehensive Loss [Abstract]
Revenue
Operating expenses:
General and administrative	4,401	5,383
Research and development	5,842	3,175
Amortization of intangible assets	167	166
Total operating expenses	10,410	8,724
Other income (expense):
Interest income	332	56
Total other income (expense)	332	56
Net loss	(10,078)	(8,668)
Other comprehensive loss:
Unrealized gain on available-for-sale securities	3	48
Comprehensive loss	$ (10,075)	$ (8,620)
Net loss per share:
Basic and diluted net loss per share	$ (0.49)	$ (0.51)
Weighted average shares used to compute net loss per common share - basic and diluted	20,679	16,842

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (10,078)	$ (8,668)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	162	153
Amortization of intangible assets	167	166
Stock-based compensation	2,361	3,420
Net premium amortization and discount on available-for-sale securities	(96)	(10)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	229	44
Other long-term assets	(107)
Accounts payable	(72)	162
Accrued expenses	98	(188)
Other current and long-term liabilities	6	(97)
Net cash used in operating activities	(7,330)	(5,018)
Cash flows from investing activities:
Purchases of property and equipment	(45)	(34)
Purchases of investments	(44,186)	(19,157)
Maturities of investments	8,500	6,315
Sales of investments		24,875
Net cash provided by (used in) investing activities	(35,731)	11,999
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock purchase plan	272	188
Proceeds from exercises of stock options	222	112
Net cash provided by financing activities	494	300
Net increase (decrease) in cash	(42,567)	7,281
Cash and cash equivalents at beginning of period	51,103	3,386
Cash and cash equivalents at end of period	8,536	10,667
Supplemental disclosure of noncash investing and financing activities:
Change in unrealized gains (losses) on available-for-sale securities	$ 3	$ 48

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 17	$ 84,202	$ (51)	$ (38,173)	$ 45,995
Balance, shares at Dec. 31, 2017	16,819
Issuance of shares upon exercise of stock options		112			112
Issuance of shares upon exercise of stock options, shares	38
Issuance of shares under employee stock purchase plan		188			188
Issuance of shares under employee stock purchase plan, shares	12
Stock-based compensation expense		3,420			3,420
Unrealized gain on available-for-sale securities			48		48
Net loss				(8,668)	(8,668)
Balance at Mar. 31, 2018	$ 17	87,922	(3)	(46,841)	41,095
Balance, shares at Mar. 31, 2018	16,869
Balance at Dec. 31, 2018	$ 21	142,032	(1)	(75,718)	$ 66,334
Balance, shares at Dec. 31, 2018	20,593				20,593
Issuance of shares upon exercise of stock options		272			$ 272
Issuance of shares upon exercise of stock options, shares	99
Issuance of shares under employee stock purchase plan		222			222
Issuance of shares under employee stock purchase plan, shares	18
Stock-based compensation expense		2,361			2,361
Unrealized gain on available-for-sale securities			3		3
Net loss				(10,078)	(10,078)
Balance at Mar. 31, 2019	$ 21	$ 144,887	$ 2	$ (85,796)	$ 59,114
Balance, shares at Mar. 31, 2019	20,710				20,710

Description Of The Business

Description Of The Business	3 Months Ended
	Mar. 31, 2019
Description Of The Business [Abstract]
Description Of The Business	1. Description of the Business  Pulse Biosciences, Inc., is a bioelectric medicine company pursuing commercial introduction of its proprietary CellFX™ System utilizing the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) platform technology. The Company’s NPS technology provides a novel, precise, non-thermal cellular treatment technology delivering nanosecond pulses of high amplitude electrical energy that clear targeted cells while sparing adjacent non-cellular tissue. The novel characteristics of the Company’s NPS mechanism of action has the potential to significantly benefit patients across multiple medical applications, including dermatology, the Company’s first planned commercial application. The Company was incorp orated in Nevada on May 19, 2014 . O n June 18, 2018, the Company reincorporated from the State of Nevada to the State of Delaware. The Company’s headquarters and research facility are located in Hayward, California. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced revenue-generating operations, does not have cash flows from operations, and will need to raise additional capital to finance its operations. There can be no assurances that the Company will be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its operating requirements.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements (“Financial Statements”) have been prepared on a basis consistent with the Company’s December 31, 2018 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements as of that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three-month period ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire year or any future periods. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the Financial Statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. Recently Adopted Accounting Pronouncement In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“Topic 842”), which amended prior accounting standards for leases. The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019. The adoption did not materially impact the Company’s Consolidated Statement of Stockholders’ Equity or Cash Flows. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the three-month period ended March 31, 2019, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, except for the adoption of ASU No. 2016-02, Leases , as of January 1, 2019. Principles of Consolidation The accompanying consolidated financial statements include the financial statements of Pulse Biosciences and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation. Net Loss per Share The Company calculates basic net loss per share by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share. Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive. The following outstanding stock options, warrants and restricted stock units were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:      Three-Month Periods Ended  March 31,  2019 2018  Common stock warrants 213,485 249,709  Common stock options 2,871,770 2,598,754  Restricted stock units 222,606 229,774  Total 3,307,861 3,078,237     Reclassification Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassifications did not impact the Company's previously reported net loss or financial position. 

Fair Value Of Financial Instrum

Fair Value Of Financial Instruments	3 Months Ended
	Mar. 31, 2019
Fair Value Of Financial Instruments [Abstract]
Fair Value Of Financial Instruments	3. Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value of financial instruments into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Level 1 - Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include money market funds. Level 2 - Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include commercial paper, corporate bonds, and asset-backed securities. Level 3 - Unobservable inputs for which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. The Company did not classify any of its investments within Level 3 of the fair value hierarchy. The following table sets forth the fair value of the Company’s financial assets measured on a recurring basis as of March 31, 2019 and December 31, 2018, respectively (in thousands):    March 31, 2019 December 31, 2018  Assets Classification Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total  Money market funds Cash and cash equivalents $ 7,773 — — $ 7,773 $ 50,703 $ — $ — $ 50,703  U.S. Treasury Securities Investments — 44,265 — 44,265 — 8,480 — 8,480  Total assets measured at fair value $ 7,773 $ 44,265 $ — $ 52,038 $ 50,703 $ 8,480 $ — $ 59,183  The Company did not have any financial liabilities measured on a recurring basis as of March 31, 2019 or December 31, 2018. During the three-month period ended March 31, 2019, there were no transfers between Level 1, Level 2 or Level 3 assets or liabilities reported at fair value on a recurring basis and the valuation techniques used did not change compared to the Company’s established practice.

Property And Equipment, Net

Property And Equipment, Net	3 Months Ended
	Mar. 31, 2019
Property And Equipment, Net [Abstract]
Property And Equipment, Net	4. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands):     March 31, December 31,  2019 2018  Leasehold improvements $ 2,248 $ 2,248  Laboratory equipment 589 518  Furniture, fixtures, and equipment 256 248  Software 117 118  Construction in progress — 33  3,210 3,165  Less: Accumulated depreciation (1,154) (992)  $ 2,056 $ 2,173   Depreciation expense was $0.2 million and $0.2 million for th e three-month periods ended March 31, 2019 and 2018, respectively.

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2019
Intangible Assets, Net [Abstract]
Intangible Assets, Net	5 . Intangible Assets, Net Intangible assets primarily consist of acquired licenses to utilize certain patents, know-how and technology relating to the Company’s NPS for biomedical applications acquired from Old Dominion University Research Foundation (“ODURF”), Eastern Virginia Medical School, and the University of Southern California. In addition, the Company entered into a Sponsored Research Agreement with Old Dominion University’s Frank Reidy Research Center for Bioelectrics, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets over an estimated useful life of 12 years. Intangible assets, net consisted of the following (in thousands):      March 31, December 31,  2019 2018  Acquired patents and licenses $ 7,985 $ 7,985  Less: Accumulated amortization (2,939) (2,772)  $ 5,046 $ 5,213 A schedule of the amortization of intangible assets for the remainder of 2019 and the succeeding five fiscal years and thereafter is as follows (in thousands):     Year Ending December 31:  2019 (remaining 9 months) $ 499  2020 665  2021 665  2022 665  2023 665  2024 665  Thereafter 1,222  $ 5,046  

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2019
Goodwill [Abstract]
Goodwill	6. Goodwill During 2014, the Company acquired three companies (the “acquisitions”) for aggregate consideration of $5.5 million. In accordance with ASC Topic 805, Business Combinations , the Company recorded goodwill of $2.8 million in connection with the acquisitions as the consideration paid exceeded the fair value of the net tangible assets and the intangible assets acquired. The Company reviews goodwill for impairment at least annually or whenever changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. Based on the Company’s annual impairment test as of December 31, 2018 the Company determined that no impairment of goodwill existed and was not aware of any indicators of impairment at such date. In addition, there were no indicators of impairment at March 31, 2019.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2019
Accrued Expenses [Abstract]
Accrued Expenses	7. Accrued Expenses Accrued expenses consisted of the following (in thousands):     March 31, December 31,  2019 2018  Compensation expense $ 672 $ 938  Accrued clinical 429 156  Professional fees 315 274  Supplies 28 53  Other 75 —  $ 1,519 $ 1,421

Stockholders' Equity And Stock-

Stockholders' Equity And Stock-Based Compensation	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity And Stock-Based Compensation [Abstract]
Stockholders' Equity And Stock-Based Compensation	8. Stockholders’ Equity and Stock-Based Compensation Rights Offering On October 25, 2018, the Company commenced a rights offering pursuant to which stockholders of record as of November 19, 2018, were issued, at no charge, one subscription right for each share of common stock then outstanding. Each right entitled the holder to purchase 0.19860755 share of the Company’s common stock for $12.57 per share (the “Rights Offering”). Stockholders who exercised their rights in full were also permitted an over-subscription right to purchase additional shares of common stock that remained unsubscribed at the expiration of the Rights Offering, subject to the availability of shares and a pro rata allocation of shares among persons exercising the oversubscription right. Upon the closing of the Rights Offering on December 6, 2018, the Rights Offering was oversubscribed. A total of 3,581,148 shares of the Company’s common stock were issued and sold in the Rights Offering for net proceeds of approximately $44.8 million. Robert W. Duggan, the Company’s Chairman of the Board of Directors and the beneficial owner of approximately 35% of the Company’s outstanding common stock prior to the Rights Offering, participated in the Rights Offering and purchased an aggregate of 3,146,226 shares for an additional investment of approximately $39.5 million. Common Stock Warrants In connection with a private placement offering of the Company’s common stock, par value $0.001 per share in 2014, the Company issued warrants as compensation to the placement agent to purchase a total of 299,625 shares of its common stock at a price of $2.67 per share (the “Private Placement Warrants”). The Private Placement Warrants are exercisable for a period of seven years. As of March 31, 2019, there were a total of 91,876 Private Placement Warrants outstanding. In connection with the closing of the Company’s initial public offering in 2016, the Company issued warrants as compensation to its underwriters to purchase a total of 574,985 shares of its common stock at a price of $5.00 per share (“the IPO Warrants”). The IPO Warrants are exercisable for a period of five years. As of March 31, 2019 , there were a total of 121,609 of the IPO Warrants outstanding. Equity Plans 2017 Equity Incentive Plan and 2017 Inducement Equity Incentive Plan The Board of Directors of the Company (the “Board”) previously adopted, and the Company’s stockholders approved, the Company’s 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan has a 10 -year term, and provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, and performance shares to employees, directors and consultants of the Company and any parent or subsidiary of the Company, as the Compensation Committee of the Board may determine. Subject to an annual evergreen increase and adjustment in the case of certain capitalization eve nts, the Company initially reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to awards under the 2017 Plan. In addition, shares remaining under the Company’s 2015 Equity Incentive Plan, as amended (the “2015 Plan”), and shares reserved but not issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under the 2017 Plan. The 2017 Plan is administered by the Board’s Compensation Committee.  Effective January 1, 2019, the Company’s Board authorized an increase in the number of shares of common stock available under the 2017 Plan by 8 23,716 shares pursuant to the evergreen provision of the 2017 Plan. Pursuant to the 2017 Plan, the 2019 share increase is determined based on the least of (i) 1,200,000 shares, (ii) 4% of the Company’s common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. As of March 31, 2019, 1,375,516 shares of common stock were available for issuance under the 2017 Plan. During November 2017, the Board adopted the 2017 Inducement Equity Incentive Plan (the “Inducement Plan”) and reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan was adopted without stockholder approval. The Inducement Plan has a 10 -year term, and provides for the grant of equity-based awards, including nonstatutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the 2017 Plan, including with respect to treatment of equity awards in the event of a “merger” or “change in control” as defined under the Inducement Plan. Options issued under the Inducement Plan may have a term up to ten years and have variable vesting provisions. New hire grants generally vest 25% upon the first anniversary of the grant and 1/ 48th monthly thereafter, over the subsequent 36 months. E quity-based awards issued under the Inducement Plan are only issuable to individuals not previously engaged as employees or non-employee directors of the Company prior to the Inducement Plan’s adoption date. As of March 31, 2019, 515,250 shares of common stock were available for issuance under the Inducement Plan. 2017 Employee Stock Purchase Plan The Board previously adopted and the stockholders approved the Company’s 2017 Employee Stock Purchase Plan (the “2017 ESPP”). The 2017 ESPP is a broad-based plan that provides employees of the Company and its designated affiliates with the opportunity to become stockholders through periodic payroll deductions that are applied towards the purchase of Company common shares at a discount from the then-current market price. Subject to adjustment in the case of certain capitalization events, a total of 250,000 common shares of the Company were available for purchase at adoption of the 2017 ESPP. Pursuant to the 2017 ESPP, the annual share increase pursuant to the evergreen provision is determined based on the least of (i) 450,000 shares, (ii) 1.5% of the Company’s common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. In January 2019, the Board determined not to increase the number of shares of common stock available under the 2017 ESPP pursuant to the evergreen provision of the 2017 ESPP. During the three-month period ended March 31, 2019, the Company issued 18,574 shares of common stock under the 2017 ESPP. As of March 31, 2019, 459,900 shares of common stock were available for issuance under the 2017 ESPP. A summary of stock option activity under the 2015 Plan, 2017 Plan and Inducement Plan for the three-months ended March 31, 2019 is presented below:     Stock Options Outstanding  Weighted  Number average  of shares exercise price  Balances — December 31, 2018 2,956,687 $ 17.04  Options granted 174,303  Options exercised (98,928)  Options canceled (9,667)  Options expired (150,625)  Balances — March 31, 2019 2,871,770 $ 17.22  Exercisable — March 31, 2019 1,446,422 $ 16.06  The table above excludes 42,500 performance stock options granted during the year ended December 31, 2018 for which the performance criteria had not been established as of March 31, 2019.  Stock-based Compensation Total stock-based compensation expense consisted of the following (in thousands):      Three-Month Periods Ended  March 31,  2019 2018  General and administrative $ 1,485 $ 2,699  Research and development 876 721  Total stock-based compensation expense $ 2,361 $ 3,420  The Company estimated the fair value of employee stock options on the grant date using the Black-Scholes option pricing model . The estimated fair value of employee stock options is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. Due to the limited trading history of the Company’s common stock, the Company utilizes a portfolio of comparable companies to estimate volatility. The fair value of employee stock options was estimated using the following weighted-average assumptions:     Three-Month Periods Ended March 31,  2019 2018  Expected term in years 0.4 - 6.1 6.1  Expected volatility 70% 70%  Risk-free interest rate 2.4 - 2.7% 2.7%  Dividend yield — —  The Company estimated the fair value of ESPP on the grant date using the Black-Scholes option pricing model . The estimated fair value of ESPP is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its own volatility in the Black-Scholes option pricing model to determine the fair value of ESPP. The fair value of ESPP was estimated using the following weighted-average assumptions:     Three-Month Periods Ended March 31,  2019 2018  Expected term in years 0.5 - 1.0 0.5 - 1.0  Expected volatility 70% 70%  Risk-free interest rate 2.5% - 2.6% 1.9% - 2.1%  Dividend yield — —    The f air value of restricted stock unit (“RSUs”) awards is determined based on the number of units granted and the closing price of the Company’s common stock as of the grant date. The estimated fair value of RSUs is recognized on a straight-line basis over the requisite service period. In the three-month period ended June 30, 2017, the Company granted 160,974 RSUs all of which vested pursuant to which no shares were issued, during June 2018 . Additional paid in capital was reduced by $0.1 million during 2018 for tax payments related to shares withheld in connection with the vesting of the RSUs. As of March 31, 2019, there was no unrecognized compensation expense related to these RSUs.  During the three-month period ended September 30, 2017, the Company granted 68,800 RSUs to certain employees which vest 50% on June 1, 2019 with the remaining 50% vesting on June 1, 2021 . In the event of a change in control, these RSUs vest 100% . The stock-based compensation expense related to these RSUs was approximately $0.1 m illion and $0.1 million for the t hree-month periods ended March 31, 2019 and March 31, 2018, respectively.

Research Grants And Agreements

Research Grants And Agreements	3 Months Ended
	Mar. 31, 2019
Research Grants And Agreements [Abstract]
Research Grants And Agreements	9. Research Grants and Agreements Sponsored Research Agreement The Company may annually sponsor research activities performed by ODURF’s Frank Reidy Research Center for Bioelectrics. During the year ended December 31, 2018, the Company agreed to sponsor $0.8 million in research during the subsequent 12 -month period to be funded through monthly payments made upon ODURF certifying, to the Company’s reasonable satisfaction, that ODURF has met its obligations pursuant to the specified task order and statement of work. The principal investigator may transfer funds with the budget as needed without the Company’s approval so long as the obligations of ODURF under the task order and statement of work remain unchanged and unimpaired. As of March 31, 2019, approximately $0.4 million remained payable under this sponsorship. In addition, during 2017, the Company agreed to provide $0.3 million in research funding to researchers affiliated with ODURF and Eastern Virginia Medical School matching funds made available to those researchers by the Virginia Biosciences Health Research Corporation. The Company’s sponsorship affords access to certain intellectual property, if any, developed during the project. As of March 31, 2019, approximately $0.1 million remained payable under this sponsorship. During the three-month periods ended March 31, 2019 and 2018, the Company paid and incurred costs relating to the sponsored research agreements equal to $0.2 million a nd $0.3 million, r espectively.

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies [Abstract]
Commitments And Contingencies	10. Commitments and Contingencies Operating Leases  During January 2017, the Company entered into a new lease agreement for premises consisting of approximately 15,700 rentable square feet located in Hayward, California. The lease commenced on July 1, 2017 and expires in August 2022, with an option to extend the lease term for an additional five years .  The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019 . Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company's right-of-use assets and related lease liabilities were as follows :     Cash paid for operating lease liabilities $ 132  Right-of-use assets recognized in exchange for new lease obligations 107   Current operating lease liabilities 396  Non-current operating lease liabilities 1,223  Total lease liabilities $ 1,619   Weighted average remaining lease term 3.42 years  Weighted average discount rate 10%  Maturities of lease liabilities as of March 31, 2019 were as follows (in thousands):     Year Ending December 31:  2019 (remaining 9 months) $ 404  2020 554  2021 574  2022 392  Total lease payments 1,924  Less imputed interest (305)  Total operating lease liabilities $ 1,619 During the three-month periods ended March 31, 2019 and 2018, rent expense, including common area maintenance charges, was approximately $59,000 and $57,000 , respectively. Legal Proceedings The Company maintains indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes and other matters relating to various claims that arise in the normal course of our business in addition to governmental and other regulatory investigations and proceedings. In addition, third parties may, from time to time, assert claims against the Company in the form of letters and other communications. The Company currently believes that these ordinary course matters will not have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions Kenneth A. Clark, a director of the Company since November 2017, is a member of the law firm of Wilson Sonsini Goodrich and Rosati (“WSGR”), which also serves as the outside corporate counsel to the Company. During the three-month periods ended March 31, 2019 and 2018, the Company incurred expenses reported in general and administrative expenses in the consolidated statement of operations for legal services rendered by WSGR totaling approximately $0.2 million and $ 0.3 million , respectively .

Summary Of Significant Accoun_2

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2019
Summary Of Significant Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements (“Financial Statements”) have been prepared on a basis consistent with the Company’s December 31, 2018 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements as of that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three-month period ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire year or any future periods.
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the Financial Statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.
Recent Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncement In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“Topic 842”), which amended prior accounting standards for leases. The Company adopted Topic 842 on January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC 840, Leases, and no retrospective adjustments were made to the comparative periods presented. The adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets (“ROU”) presented within other assets and operating lease liabilities of approximately $0.1 million as of January 1, 2019. The adoption did not materially impact the Company’s Consolidated Statement of Stockholders’ Equity or Cash Flows.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the three-month period ended March 31, 2019, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, except for the adoption of ASU No. 2016-02, Leases , as of January 1, 2019.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the financial statements of Pulse Biosciences and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation.
Net Loss Per Share	Net Loss per Share The Company calculates basic net loss per share by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share. Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive. The following outstanding stock options, warrants and restricted stock units were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:      Three-Month Periods Ended  March 31,  2019 2018  Common stock warrants 213,485 249,709  Common stock options 2,871,770 2,598,754  Restricted stock units 222,606 229,774  Total 3,307,861 3,078,237    
Reclassification	Reclassification Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassifications did not impact the Company's previously reported net loss or financial position.

Summary Of Significant Accoun_3

Summary Of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Summary Of Significant Accounting Policies [Abstract]
Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share	   Three-Month Periods Ended  March 31,  2019 2018  Common stock warrants 213,485 249,709  Common stock options 2,871,770 2,598,754  Restricted stock units 222,606 229,774  Total 3,307,861 3,078,237  

Fair Value Of Financial Instr_2

Fair Value Of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Of Financial Instruments [Abstract]
Fair Value Of Financial Assets Measured On A Recurring Basis	  March 31, 2019 December 31, 2018  Assets Classification Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total  Money market funds Cash and cash equivalents $ 7,773 — — $ 7,773 $ 50,703 $ — $ — $ 50,703  U.S. Treasury Securities Investments — 44,265 — 44,265 — 8,480 — 8,480  Total assets measured at fair value $ 7,773 $ 44,265 $ — $ 52,038 $ 50,703 $ 8,480 $ — $ 59,183 

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Property And Equipment, Net [Abstract]
Schedule Of Property And Equipment, Net	   March 31, December 31,  2019 2018  Leasehold improvements $ 2,248 $ 2,248  Laboratory equipment 589 518  Furniture, fixtures, and equipment 256 248  Software 117 118  Construction in progress — 33  3,210 3,165  Less: Accumulated depreciation (1,154) (992)  $ 2,056 $ 2,173 

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Intangible Assets, Net [Abstract]
Schedule Of Intangible Assets, Net	   March 31, December 31,  2019 2018  Acquired patents and licenses $ 7,985 $ 7,985  Less: Accumulated amortization (2,939) (2,772)  $ 5,046 $ 5,213 
Schedule Of Amortization Of Intangible Assets	  Year Ending December 31:  2019 (remaining 9 months) $ 499  2020 665  2021 665  2022 665  2023 665  2024 665  Thereafter 1,222  $ 5,046 

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2019
Accrued Expenses [Abstract]
Schedule Of Accrued Expenses	   March 31, December 31,  2019 2018  Compensation expense $ 672 $ 938  Accrued clinical 429 156  Professional fees 315 274  Supplies 28 53  Other 75 —  $ 1,519 $ 1,421 

Stockholders' Equity And Stoc_2

Stockholders' Equity And Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity [Line Items]
Summary Of Stock Option Activity	  Stock Options Outstanding  Weighted  Number average  of shares exercise price  Balances — December 31, 2018 2,956,687 $ 17.04  Options granted 174,303  Options exercised (98,928)  Options canceled (9,667)  Options expired (150,625)  Balances — March 31, 2019 2,871,770 $ 17.22  Exercisable — March 31, 2019 1,446,422 $ 16.06 
Schedule Of Fair Value Of Employee Stock Options	  Three-Month Periods Ended March 31,  2019 2018  Expected term in years 0.4 - 6.1 6.1  Expected volatility 70% 70%  Risk-free interest rate 2.4 - 2.7% 2.7%  Dividend yield — — 
Summary Of Stock-Based Compensation Expense	   Three-Month Periods Ended  March 31,  2019 2018  General and administrative $ 1,485 $ 2,699  Research and development 876 721  Total stock-based compensation expense $ 2,361 $ 3,420 
2017 Employee Stock Purchase Plan [Member]
Stockholders' Equity [Line Items]
Schedule Of Fair Value Of Employee Stock Options	  Three-Month Periods Ended March 31,  2019 2018  Expected term in years 0.5 - 1.0 0.5 - 1.0  Expected volatility 70% 70%  Risk-free interest rate 2.5% - 2.6% 1.9% - 2.1%  Dividend yield — — 

Commitments And Contingencies (

Commitments And Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies [Abstract]
Schedule Of Information Related To Right-Of-Use Assets And Lease Liabilities	  Cash paid for operating lease liabilities $ 132  Right-of-use assets recognized in exchange for new lease obligations 107   Current operating lease liabilities 396  Non-current operating lease liabilities 1,223  Total lease liabilities $ 1,619   Weighted average remaining lease term 3.42 years  Weighted average discount rate 10% 
Schedule Of Future Minimum Lease Payments	  Year Ending December 31:  2019 (remaining 9 months) $ 404  2020 554  2021 574  2022 392  Total lease payments 1,924  Less imputed interest (305)  Total operating lease liabilities $ 1,619 

Summary Of Significant Accoun_4

Summary Of Significant Accounting Policies (Narrative) (Details) $ in Millions	Jan. 01, 2019USD ($)
Accounting Standards Update 2016-02 [Member]
Summary Of Significant Accounting Policies [Line Items]
Increase in total assets and liabilities due to recording of operating lease right-of-use assets and operating lease liabilities	$ 0.1

Summary Of Significant Accoun_5

Summary Of Significant Accounting Policies (Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,307,861	3,078,237
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	213,485	249,709
Options outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,871,770	2,598,754
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	222,606	229,774

Fair Value Of Financial Instr_3

Fair Value Of Financial Instruments (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value Of Financial Instruments [Abstract]
Liabilities measured at fair value	$ 0	$ 0
Transfers between level 1, 2, or 3	$ 0

Fair Value Of Financial Instr_4

Fair Value Of Financial Instruments (Fair Value Of Financial Assets Measured On A Recurring Basis) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
ASSETS
Total assets measured at fair value	$ 52,038	$ 59,183
Cash and cash equivalents [Member] | Money market funds [Member]
ASSETS
Total cash and cash equivalents	7,773	50,703
Investments [Member] | U.S. Treasury Securities [Member]
ASSETS
Total investments	44,265	8,480
Level 1 [Member]
ASSETS
Total assets measured at fair value	7,773	50,703
Level 1 [Member] | Cash and cash equivalents [Member] | Money market funds [Member]
ASSETS
Total cash and cash equivalents	7,773	50,703
Level 2 [Member]
ASSETS
Total assets measured at fair value	44,265	8,480
Level 2 [Member] | Investments [Member] | U.S. Treasury Securities [Member]
ASSETS
Total investments	$ 44,265	$ 8,480

Property And Equipment, Net (Na

Property And Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Property And Equipment, Net [Abstract]
Depreciation expense	$ 162	$ 153

Property And Equipment, Net (Sc

Property And Equipment, Net (Schedule Of Property And Equipment, Net) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 3,210	$ 3,165
Less: Accumulated depreciation	(1,154)	(992)
Equipment, net	2,056	2,173
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	2,248	2,248
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	589	518
Furniture, Fixtures, And Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 256	248
Software [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross		$ 33

Intangible Assets, Net (Narrati

Intangible Assets, Net (Narrative) (Details)	3 Months Ended
	Mar. 31, 2019
Intangible Assets, Net [Abstract]
Intangible asset useful life	12 years

Intangible Assets, Net (Schedul

Intangible Assets, Net (Schedule Of Intangible Assets, Net) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Less: Accumulated amortization	$ (2,939)	$ (2,772)
Intangible assets, net	5,046	5,213
Acquired Patents And Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 7,985	$ 7,985

Intangible Assets, Net (Sched_2

Intangible Assets, Net (Schedule Of Amortization Of Intangible Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Intangible Assets, Net [Abstract]
2019 (remaining 9 months)	$ 499
2020	665
2021	665
2022	665
2023	665
2024	665
Thereafter	1,222
Intangible assets, net	$ 5,046	$ 5,213

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2014	Dec. 31, 2018
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Goodwill	$ 2,791,000	$ 2,800,000	$ 2,791,000
Goodwill impairment	$ 0
TPI, BEM And NB [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Aggregate consideration		$ 5,500,000

Accrued Expenses (Schedule Of A

Accrued Expenses (Schedule Of Accrued Expenses) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accrued Expenses [Abstract]
Compensation expense	$ 672	$ 938
Accrued clinical	429	156
Professional fees	315	274
Supplies	28	53
Other	75
Accrued expenses	$ 1,519	$ 1,421

Stockholders' Equity And Stoc_3

Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands

Dec. 06, 2018

Jan. 01, 2018

Mar. 31, 2019

Mar. 31, 2018

Sep. 30, 2017

Dec. 31, 2017

Dec. 31, 2014

Dec. 31, 2018

Oct. 25, 2018

Nov. 30, 2017

Jun. 30, 2017

Dec. 31, 2016

Stockholders' Equity [Line Items]

Common stock, par value

$ 0.001

$ 0.001

Common stock, shares issued

20,710,000

20,593,000

Total stock-based compensation expense

$ 2,361

$ 3,420

Cash received from option exercises

$ 222

112

2017 Employee Stock Purchase Plan [Member]

Stockholders' Equity [Line Items]

Common stock, shares issued

18,574

Shares authorized

250,000

Additional common stock reserved for issuance

459,900

Increase in shares available for issuance threshold of common stock outstanding, number of shares

450,000

Increase in shares available for issuance threshold of common stock outstanding, percent outstanding

1.50%

2017 Inducement Equity Incentive Plan [Member]

Stockholders' Equity [Line Items]

Term period

10 years

Shares authorized

515,250

1,000,000

2017 Plan [Member]

Stockholders' Equity [Line Items]

Term period

10 years

Shares authorized

1,500,000

Additional common stock reserved for issuance

823,716

1,375,516

Increase in shares available for issuance threshold of common stock outstanding, number of shares

1,200,000

Increase in shares available for issuance threshold of common stock outstanding, percent outstanding

4.00%

First Vesting Portion [Member] | 2017 Inducement Equity Incentive Plan [Member]

Stockholders' Equity [Line Items]

Vesting percentage

25.00%

Second Vesting Portion (Per Month) [Member] | 2017 Inducement Equity Incentive Plan [Member]

Stockholders' Equity [Line Items]

Vesting period

36 months

Vesting percentage

0.02%

Sales, general and administrative [Member]

Stockholders' Equity [Line Items]

Total stock-based compensation expense

$ 1,485

2,699

Research and development [Member]

Stockholders' Equity [Line Items]

Total stock-based compensation expense

$ 876

721

Options outstanding [Member]

Stockholders' Equity [Line Items]

Options granted

174,303

Warrants exercised

98,928

Exercise price

$ 16.06

Restricted Stock Units [Member]

Stockholders' Equity [Line Items]

Shares available for grant

68,800

Total stock-based compensation expense

$ 100

$ 100

Restricted Stock Units [Member] | First Vesting Portion [Member]

Stockholders' Equity [Line Items]

Vesting percentage

50.00%

Cliff vest date

Jun. 1, 2019

Restricted Stock Units [Member] | Second Vesting Portion (Per Month) [Member]

Stockholders' Equity [Line Items]

Vesting percentage

50.00%

Cliff vest date

Jun. 1, 2021

Restricted Stock Units [Member] | Change In Control [Member]

Stockholders' Equity [Line Items]

Vesting percentage

100.00%

Officer [Member]

Stockholders' Equity [Line Items]

Cliff vest date

Jun. 30, 2018

Officer [Member] | Restricted Stock Units [Member]

Stockholders' Equity [Line Items]

Shares available for grant

160,974

Common Stock

Stockholders' Equity [Line Items]

Warrants exercised

99,000

38,000

Common Stock | Rights Offering [Member]

Stockholders' Equity [Line Items]

Net proceeds

$ 44,800

Right entitlement to holder

3,581,148

0.19860755

Exercise price of warrants/rights

$ 12.57

Common Stock | Chairman, Robert W. Duggan [Member] | Rights Offering [Member]

Stockholders' Equity [Line Items]

Ownership percentage

35.00%

Shares purchased

3,146,226

Investment

$ 39,500

MDB Capital Group, LLC [Member] | Initial Public Offering [Member]

Stockholders' Equity [Line Items]

Price per share

$ 5

Warrants/rights outstanding

121,609

Exercisable period of warrants or rights

5 years

Number of common shares called by issuance of warrants

574,985

MDB Capital Group, LLC [Member] | Private Placement [Member]

Stockholders' Equity [Line Items]

Price per share

$ 2.67

Warrants/rights outstanding

91,876

Exercisable period of warrants or rights

7 years

Number of common shares called by issuance of warrants

299,625

Stockholders' Equity And Stoc_4

Stockholders' Equity And Stock-Based Compensation (Summary Of Stock Option Activity) (Details) - Options outstanding [Member]	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Beginning Balance, Number of shares | shares	2,956,687
Options granted, Number of shares | shares	174,303
Options exercised, Number of shares | shares	(98,928)
Options canceled, Number of shares | shares	(9,667)
Options expired, Number of shares | shares	(150,625)
Ending Balance, Number of shares | shares	2,871,770
Exercisable, Number of shares | shares	1,446,422
Beginning Balance, Weighted average exercise price per share | $ / shares	$ 17.04
Options granted, Weighted average exercise price per share | $ / shares
Options exercised, Weighted average exercise price per share | $ / shares
Options canceled, Weighted average exercise price per share | $ / shares
Options expired, Weighted average exercise price per share | $ / shares
Ending Balance, Weighted average exercise price per share | $ / shares	17.22
Exercisable, Weighted average exercise price per share | $ / shares	$ 16.06

Stockholders' Equity And Stoc_5

Stockholders' Equity And Stock-Based Compensation (Schedule Of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 2,361	$ 3,420
Sales, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	1,485	2,699
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 876	$ 721

Stockholders' Equity And Stoc_6

Stockholders' Equity And Stock-Based Compensation (Schedule Of Fair Value Of Employee Stock Options) (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Options outstanding [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	70.00%	70.00%
Risk-free interest rate		2.70%
Risk-free interest rate, minimum	2.40%
Risk-free interest rate, maximum	2.70%
Dividend yield
Options outstanding [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	4 months 24 days	6 years 1 month 6 days
Risk-free interest rate		2.70%
Options outstanding [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 1 month 6 days
2017 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	70.00%	70.00%
Risk-free interest rate, minimum	2.50%	1.90%
Risk-free interest rate, maximum	2.60%	2.10%
Dividend yield
2017 Employee Stock Purchase Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 months	6 months
2017 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	1 year	1 year

Stockholders' Equity And Stoc_7

Stockholders' Equity And Stock-Based Compensation (Summary Of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Total stock-based compensation expense	$ 2,361	$ 3,420
Sales, general and administrative [Member]
Total stock-based compensation expense	1,485	2,699
Research and development [Member]
Total stock-based compensation expense	$ 876	$ 721

Research Grants And Agreements

Research Grants And Agreements (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	$ 5,842	$ 3,175
Sponsored Research Agreement ("SRA") [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	$ 200	$ 300
ODURF [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Period of time for Sponsored Research Agreement ("SRA")	12 months
ODURF [Member] | Sponsored Research Agreement ("SRA") [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense			$ 800
Remaining sponsorship	$ 400
ODURF And Eastern Virginia Medical School [Member] | Sponsored Research Agreement ("SRA") [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense			$ 300
Remaining sponsorship	$ 100

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Jan. 31, 2017ft²
Commitments And Contingencies [Abstract]
Area Of Lease | ft²			15,700
Rent expense, including common area maintenance charges | $	$ 59	$ 57

Commitments And Contingencies_3

Commitments And Contingencies (Schedule Of Information Related To Right-Of-Use Assets And Lease Liabilities) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Commitments And Contingencies [Abstract]
Cash paid for operating lease liabilities	$ 132
Right-of-use assets recognized in exchange for new lease obligations	107
Current operating lease liabilities	396
Non-current operating lease liabilities	1,223
Total lease liabilities	$ 1,619
Weighted average remaining lease term	3 years 5 months 1 day
Weighted average discount rate	10.00%

Commitments And Contingencies_4

Commitments And Contingencies (Schedule Of Future Minimum Lease Payments) (Details) $ in Thousands	Mar. 31, 2019USD ($)
Commitments And Contingencies [Abstract]
2019 (remaining 9 months)	$ 404
2020	554
2021	574
2022	392
Total minimum lease payments	1,924
Less imputed interest	(305)
Total operating lease liabilities	$ 1,619

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 06, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Oct. 25, 2018
Related Party Transaction [Line Items]
Common stock, par value		$ 0.001		$ 0.001
Wilson Sonsini Goodrich And Rosati (WSGR) [Member]
Related Party Transaction [Line Items]
Related party expenses		$ 0.2	$ 0.3
Common Stock | Rights Offering [Member]
Related Party Transaction [Line Items]
Right entitlement to holder	3,581,148				0.19860755
Exercise price of warrants/rights					$ 12.57
Net proceeds	$ 44.8
Common Stock | Chairman, Robert W. Duggan [Member] | Rights Offering [Member]
Related Party Transaction [Line Items]
Ownership percentage	35.00%